BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

February 17, 2014 8:00 AM UTC

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and oral formulations of tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA date for both applications is June 20.

The committee will also discuss an NDA from Durata Therapeutics Inc. (NASDAQ:DRTX) for IV dalbavancin (RQ-00000002) to treat ABSSSIs. Dalbavancin has a May 26 PDUFA date...